Navigation Links
InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
Date:9/2/2008

a 14-day study of ITMN-191 in combination with Pegasys(R) (peginterferon alfa-2a) and Copegus(R) (ribavirin). The study is proceeding as planned. Top-line results from the triple combination study are anticipated to be released in the fourth quarter of 2008.

About Hepatitis C

The hepatitis C virus (HCV) is transmitted primarily through blood or blood products. HCV chronically affects 180 million people worldwide, which makes it over four times more prevalent than HIV. It is a leading cause of cirrhosis, liver cancer and liver failure, despite the fact that many patients can be cured.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a pipeline portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone as a possible therapeutic candidate for the treatment of patients with IPF and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) in Phase 1b, a second-generation HCV protease inhibitor research program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit http://www.intermune.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation the statements related to anticipated product development timelines. All forward-looking statements and other information included
'/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
6. InterMune to Present at the SIGnificant Options in Healthcare Conference
7. Evotec Expands Collaboration With InterMune
8. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
9. InterMune to Present at Deutsche Bank Health Care Conference
10. InterMune to Present at Bank of America Health Care Conference
11. InterMune to Present at Citigroup Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... the Institute for Molecular Medicine Finland (FIMM), University ... a novel "man and machine" decision support system ... was described in PLOS One scientific ... on computer vision algorithms similar to those used ... only the diagnostically most relevant areas. Tablet computers ...
(Date:8/21/2014)... , August 21, 2014 ... ) has announced the addition of the  ... to their offering.       (Logo: ... hormone therapy, is a means of replacing ... by the body. This type of therapy ...
(Date:8/21/2014)... 2014 The College of New Rochelle ... in the Mid-Hudson Region to be designated as a ... applications from qualified “high-technology” businesses that align with the ... to have been selected for the START-UP NY program ... to stimulate economic development in New York by growing ...
(Date:8/21/2014)... YORK , Aug. 21, 2014 ... congratulates Immune Pharmaceuticals Inc., a biotechnology company, on ... Market.  Immune previously traded on OTCQX®, the best ... by OTC Markets Group. Logo - ... Pharmaceuticals on the successful execution of its growth ...
Breaking Biology Technology:A novel 'man and machine' decision support system makes malaria diagnostics more effective 2Global Hormone Replacement Therapy Market 2014-2018: Key Vendors are Actavis, Bayer, Merck & Co, Novartis and Novo Nordisk 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 3OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2
... Sequence Analysis Problem -, - Exhibit to Spotlight ... MISSION VIEJO, Calif., Sept. 26 Supporting ... genomic search,technology, SLIM Search, Inc. announces it is ... Next Generation,Sequencing Conference. The conference will review new ...
... Phil Coggins to Continue as President and CSO, ... Osprey,Pharmaceuticals, Ltd., a privately held biotechnology company developing,first-in-class ... today the appointment of Jack M. Anthony to ... the position of,CEO will continue as President and ...
... September 26 XTL,Biopharmaceuticals Ltd. (NASDAQ: XTLB ... September 24, 2007, the Company received a NASDAQ ... with the minimum,$10 million shareholders, equity requirement for ... forth in Marketplace Rule 4450(a)(3), and that,its ADRs ...
Cached Biology Technology:SLIM Search, Inc. Sponsors Next Generation Sequencing Conference for the Biomedical Market 2SLIM Search, Inc. Sponsors Next Generation Sequencing Conference for the Biomedical Market 3SLIM Search, Inc. Sponsors Next Generation Sequencing Conference for the Biomedical Market 4Osprey Pharmaceuticals Names Jack M. Anthony as CEO 2Osprey Pharmaceuticals Names Jack M. Anthony as CEO 3XTL to Appeal NASDAQ Staff Determination; XTL May Transfer its ADR Listing to the NASDAQ Capital Market 2XTL to Appeal NASDAQ Staff Determination; XTL May Transfer its ADR Listing to the NASDAQ Capital Market 3
(Date:8/21/2014)... geologist Juliane Mller the Fram Strait is a key region ... this passage between Greenland and Svalbard warm Atlantic water flows ... west side cold Arctic water masses and sea ice push ... A considerable portion of the Atlantic water cools here on ... The circulation of the water caused in this manner drives ...
(Date:8/21/2014)... designed by an international standards process, will be available ... an invited review published in the OnlineFirst version of ... the official journal of the American Society for Parenteral ... reduce the occurrence of misconnection that can be harmful ... are used to join medical devices, components, and accessories ...
(Date:8/21/2014)... in severe abdominal pain, vomiting and systemic inflammation. Every ... with the disease resulting in 1000 deaths. There is ... fluid and nutritional support. , Dr Jason Bruce, ... research, said "The major causes of pancreatitis include bile ... combined with a high fat diet. In fact, the ...
Breaking Biology News(10 mins):Arctic sea ice influenced force of the Gulf Stream 2Arctic sea ice influenced force of the Gulf Stream 3New feeding tube connectors will improve patient safety 2Insulin offers new hope for the treatment of acute pancreatitis 2
... Spanish . Making DNA sequences being passed through ... point that they take on the form of diminutive spaghetti. This ... of the lines of research in which CIC microGUNE is working, ... are shortly to apply for a patent. The technique basically consists ...
... New York / Heidelberg, 6 April 2011 The ... pads of many insects, lizards and spiders give them the ... James Bullock and Walter Federle from the University of Cambridge ... away these adhesive hairs from surfaces are what allows beetles ...
... used to rehabilitate the arms and hands of people who ... the University of Southampton. In a paper to be ... and Technology (IET) Assisted Living Conference, Dr Geoff Merrett, a ... and evaluation of three technologies which could help people who ...
Cached Biology News:DNA stretching -- A new technique being carried out at CIC microGUNE to detect illnesses 2Nature helps to solve a sticky problem 2Scientists develop new technology for stroke rehabilitation 2
Custom LNA Oligonucleotide synthesis ,High quality Custom LNA Oligonucleotides are available for a variety of different specialty applications and innovative products. ,Please inquire for further...
... Plus is a chemiluminescent signal enhancing ... to boost the signal obtained with ... kits. ChemiLucent™ Plus is derived from ... conjugated complex- or chemiluminescent substrate enhancers, ...
... Multi-Disciplinary Team The Schleicher & ... stand-alone work center dedicated to custom ... The facilitys experienced project teams, comprised ... Marketing professionals, work closely with collaborators ...
... microRNA (miRNA) expression profiling service using Paraflo ... highly sensitive and specific direct detection of ... mature miRNA of all species available in ... database (Release 8.2). Our service is comprehensive ...
Biology Products: